How to buy Pfizer shares | $36

Own Pfizer shares in just a few minutes.

Fact checked
Pfizer logo

Pfizer Inc (PFE) is a leading drug manufacturers—general business based in the US. It opened the day at $36.34 after a previous close of $36.25. During the day the price has varied from a low of $35.965 to a high of $36.3779. The latest price was $36 (25 minute delay). Pfizer is listed on the NYSE and employs 88,300 staff. All prices are listed in US Dollars.

How to buy shares in Pfizer

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: PFE in this case.
  5. Research Pfizer shares. The platform should provide the latest information available.
  6. Buy your Pfizer shares. It's that simple.

How has Coronavirus impacted Pfizer's share price?

Since the stock market crash in March caused by coronavirus, Pfizer's share price has had significant positive movement.

Its last market close was $36, which is 0.78% up on its pre-crash value of $35.72 and 29.12% up on the lowest point reached during the March crash when the shares fell as low as $27.88.

If you had bought $1,000 worth of Pfizer shares at the start of February 2020, those shares would have been worth $759.54 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $959.76.

Pfizer share price

Use our graph to track the performance of PFE stocks over time.

Pfizer shares at a glance

Information last updated 2020-09-23.
Open$36.34
High$36.3779
Low$35.965
Close$36
Previous close$36.25
Change $-0.25
Change % -0.69%
Volume 21,667,143
Information last updated 2020-09-20.
52-week range$27.88 - $40.97
50-day moving average $37.6162
200-day moving average $35.7675
Wall St. target price$41.79
PE ratio 14.5534
Dividend yield $1.52 (4.13%)
Earnings per share (TTM) $2.526
Promoted
eToro Free Stocks

Invest in Pfizer shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Your first 50 trades are free with Fineco, until 30/09/2020. T&Cs apply. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.

Is it a good time to buy Pfizer stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Pfizer price performance over time

Historical closes compared with the last close of $36

1 week (2020-09-14) -2.73%
1 month (2020-08-24) -7.31%
3 months (2020-06-24) 11.84%
6 months (2020-03-24) 21.21%
1 year (2019-09-20) -1.88%
2 years (2018-09-21) -18.29%
3 years (2017-09-21) 0.08%
5 years (2015-09-21) 11.04%

Is Pfizer under- or over-valued?

Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pfizer's P/E ratio

Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Pfizer shares trade at around 15x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Pfizer's P/E ratio is best considered in relation to those of others within the drug manufacturers—general industry or those of similar companies.

Pfizer's PEG ratio

Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4141. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Pfizer's PEG ratio in relation to those of similar companies.

Pfizer's EBITDA

Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $20.1 billion (£15.8 billion).

The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.

To put Pfizer's EBITDA into context you can compare it against that of similar companies.

Pfizer financials

Revenue TTM $49.2 billion
Operating margin TTM 29.82%
Gross profit TTM $41.7 billion
Return on assets TTM 5.49%
Return on equity TTM 22.81%
Profit margin 28.81%
Book value $11.584
Market capitalisation $203.5 billion

TTM: trailing 12 months

How to short and sell Pfizer shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "PFE.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 45.2 million Pfizer shares held short by investors – that's known as Pfizer's "short interest". This figure is 15.5% down from 53.5 million last month.

There are a few different ways that this level of interest in shorting Pfizer shares can be evaluated.

Pfizer's "short interest ratio" (SIR)

Pfizer's "short interest ratio" (SIR) is the quantity of Pfizer shares currently shorted divided by the average quantity of Pfizer shares traded daily (recently around 21.5 million). Pfizer's SIR currently stands at 2.1. In other words for every 100,000 Pfizer shares traded daily on the market, roughly 2100 shares are currently held short.

To gain some more context, you can compare Pfizer's short interest ratio against those of similar companies.

However Pfizer's short interest can also be evaluated against the total number of Pfizer shares, or, against the total number of tradable Pfizer shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pfizer's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Pfizer shares in existence, roughly 10 shares are currently held short) or 0.0081% of the tradable shares (for every 100,000 tradable Pfizer shares, roughly 8 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pfizer.

Find out more about how you can short Pfizer stock.

Pfizer's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Pfizer's total ESG risk score

Total ESG risk: 33.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 08/01/2020) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Pfizer's total ESG risk score against those of similar companies.

Pfizer's environmental score

Environmental score: 7/100

Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Pfizer's social score

Social score: 18.47/100

Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Pfizer's governance score

Governance score: 13.68/100

Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Pfizer's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Pfizer Inc was last rated for ESG on: 2020-08-01.

Total ESG score 33.15
Total ESG percentile 60.54
Environmental score 7
Environmental score percentile 6
Social score 18.47
Social score percentile 6
Governance score 13.68
Governance score percentile 6
Level of controversy 3

Pfizer share dividends

59%

Dividend payout ratio: 58.5% of net profits

Recently Pfizer has paid out, on average, around 58.5% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.13% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 4.13% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.52 per share.

Pfizer's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Pfizer's most recent dividend payout was on 1 September 2020. The latest dividend was paid out to all shareholders who bought their shares by 30 July 2020 (the "ex-dividend date").

Pfizer's dividend payout ratio is perhaps best considered in relation to those of similar companies.

Have Pfizer's shares ever split?

Pfizer's shares were split on a 3:1 basis on 1 July 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.

Pfizer share price volatility

Over the last 12 months, Pfizer's shares have ranged in value from as little as $27.88 up to $40.97. A popular way to gauge a stock's volatility is its "beta".

PFE.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.6589. This would suggest that Pfizer's shares are less volatile than average (for this exchange).

To put Pfizer's beta into context you can compare it against those of similar companies.

Pfizer overview

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and research collaboration and license agreement with BioInvent International AB. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site